Results-Financial results for quarter and financial year ended 31 March 2026

Revenue growth above 20%Profit growth above 25%Results View source PDF Explain this filing

SURAKSHA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-5.1%Reaction day

₹322.00

prior close

₹320.10

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.1%-5.2% vs market

Healthcare Service Provider peers, median of 26sector-0.4%-4.6% vs sector

On the reaction day the stock moved 5.2 pts less than Nifty Microcap 250 and 4.6 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-5.4

10m

-6.4

15m

-6.2

30m

-6.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-5.1+0.1-5.2-0.4-4.6

Next day

-7.5+1.7-9.1-1.3-6.2

-8.4+2.4-10.8-0.6-7.8

-9.9+2.4-12.3+1.8-11.7

-10.2+1.7-12.0+0.2-10.5

-13.0+0.6-13.6-3.0-10.1

-9.2+1.9-11.1-2.1-7.1

15d

-16.2+4.9-21.1-0.6-15.6

-13.5+8.9-22.4+1.1-14.6

-19.6+7.5-27.1-5.5-14.1

-0.0+13.6-13.6+0.7-0.8

UpDownMarket · Nifty Microcap 250Sector · Healthcare Service Provider peers, median of 26Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Suraksha Diagnostic reported standalone revenue of ₹30,068 lakhs for FY2026, up 20.7% from ₹24,910 lakhs in FY2025, meeting the 20% revenue growth threshold. Profit after tax grew modestly by 1.9% to ₹3,406 lakhs versus ₹3,344 lakhs in the prior year. The company proposed a dividend of ₹0.50 per share (25% payout) for FY2025-26, a notable improvement from zero dividend the previous year. The auditor issued an unmodified (clean) opinion with no qualifications or going concern concerns. A dispute with the Government of Meghalaya involving a step-down subsidiary has resulted in operational losses, with ₹392.20 lakhs of investments and loans under assessment. The company acquired Fetomat Wellness Private Limited in April 2025, making it a subsidiary.

Likely market impact

Revenue growth of 20.7% indicates strong business expansion, but PAT growth of only 1.9% suggests margin pressure or increased costs. The clean audit opinion and dividend announcement are positive signals for shareholders. The disputed subsidiary amount warrants monitoring.